Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab

Cancer

Volumn 119, Issue 19, 2013, Pages 3479-3488

  Huang, Raymond Y ^a   Rahman, Rifaquat ^b   Hamdan, Alhafidz ^a   Kane, Caroline ^a   Chen, Christina ^b   Norden, Andrew D ^a   Reardon, David A ^a   Mukundun, Srinivasan ^a   Wen, Patrick Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

bevacizumab; glioblastoma; magnetic resonance imaging; survival; volumetric analysis

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

BEVACIZUMAB; GLIOBLASTOMA; MAGNETIC RESONANCE IMAGING; SURVIVAL; VOLUMETRIC ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884909119     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28210     Document Type: Article

References (26)

1. Central Brain Tumor Registry of the United States. 2007-2008 Primary brain tumors in the United States. Statistical report: 2000-2004 data. http://www.cbtrus.org/reports/2007-2008/2007report.pdf.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-2578.
3. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27: 740-745.
4. Norden AD, Drappatz J, Muzikansky A, et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009; 92: 149-155.
5. Plate KH, Breier G, Risau W,. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol. 1994; 4: 207-218.
6. Ferrara N, Gerber H-P, LeCouter J,. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676.
7. Hicklin DJ, Ellis LM,. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23: 1011-1027.
8. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-4729.
9. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-4740.
10. Avastin (bevacizumab). Prescribing information. South San Francisco, CA: Genentech; 2012. http://www.gene.com/gene/products/information/pdf/avastin- prescribing.pdf.
11. Jakobsen JN, Hasselbalch B, Stockhausen M-T, Lassen U, Poulsen HS,. Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother. 2011; 12: 825-833.
12. Chamberlain MC,. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer. 2010; 116: 3988-3999.
13. Iliadis G, Kotoula V, Chatzisotiriou A, et al. Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer. 2012; 12: 3.
14. Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012; 117: 851-859.
15. Dempsey MF, Condon BR, Hadley DM,. Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am J Neuroradiol. 2005; 26: 770-776.
16. Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, Reznek RH,. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol. 2000; 73: 1178-1184.
17. Hopper KD, Kasales CJ, Eggli KD, et al. The impact of 2D versus 3D quantitation of tumor bulk determination on current methods of assessing response to treatment. J Comput Assist Tomogr. 1996; 20: 930-937.
18. Shi W, Wildrick D, Sawaya R,. Volumetric measurement of brain tumors from MR imaging. J Neurooncol. 1998; 37: 87-93.
19. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70: 779-787.
20. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB,. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011; 13: 401-409.
21. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28: 1963-1972.
22. Pieper S, Halle M, Kikinis R,. 3D Slicer. In: Proceedings of the 1st IEEE International Symposium on Biomedical Imaging: From Nano to Macro 2004. Arlington, VA; 2004: 632-635.
23. Pieper S, Lorensen B, Schroeder W, Kikinis R,. The NA-MIC Kit: ITK, VTK, Pipelines, Grids and 3D Slicer as An Open Platform for the Medical Image Computing Community. In: Proceedings of the 3rd IEEE International Symposium on Biomedical Imaging: Macro to Nano 2006. Arlington, VA; 2006: 698-701.
24. Prados M, Cloughesy T, Samant M, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011; 13: 143-151.
25. Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB,. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 1977; 47: 329-335.
26. Wang MY, Cheng JL, Han YH, Li YL, Dai JP, Shi DP,. Measurement of tumor size in adult glioblastoma: classical cross-sectional criteria on 2D MRI or volumetric criteria on high resolution 3D MRI? Eur J Radiol. 2012; 81: 2370-2374.